Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Gliosarcoma 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Tuberculosis, Pulmonary 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Esthesioneuroblastoma, Olfactory 1Endometrial Neoplasms 1Colonic Neoplasms 1Chordoma 1Breast Neoplasms, Male 1

Interventions

Rituximab 55Cyclophosphamide 41Lenalidomide 25Vincristine 23Doxorubicin 22Prednisone 21Etoposide 16ibrutinib 12Gemcitabine 12fludarabine phosphate 10fludarabine 10Peripheral Blood Stem Cell Transplantation 10Carboplatin 10Bendamustine Hydrochloride 10Ifosfamide 9Filgrastim 8polatuzumab vedotin 7obinutuzumab 7Oxaliplatin 7Mycophenolic Acid 7Methotrexate 6Cyclosporine 6venetoclax 5tafasitamab 5Vorinostat 5Radiotherapy 5R-CHOP protocol 5Prednisolone 5Melphalan 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × Fluorodeoxyglucose F18 × Clear all
NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington

Phase 1/2 Recruiting
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡